Basic Medical Theory Research

[1] Crow MK.Pathogenesis of systemic lupus erythematosus: risks,mechanisms and therapeutic targets[J].Ann Rheum Dis,2023.
[2] Tsang ASMWP,Bultink IEM, Heslinga M,et al.The relati onship between remission and health-related quality of life in a cohort of SLE patients[J].Rheumatology(Oxford),2019,58 (4):628-35.
[3] McHugh J.New evidence for the'cusp theory'to explain HLA associations in SLE[J].Nat Rev Rheumatol,2022,18(10):552.
[4] Kuo CF,Grainge MJ,Valdes AM, et al.Familial Aggregation of Systemic Lupus Erythematosus and Coaggregation of Autoim mune Diseases in Affected Families[J].JAMA Intern Med,2015, 175(9):1518-26.
[5] Hiraki LT.APOL1 Gene-Implications for Systemic Lupus Erythematosus[J].J Rheumatol,2020,47(8):1155-7.
[6] Rider V,Abdou NI,Kimler BF,et al.Gender Bias in Human Systemic Lupus Erythematosus:A Problem of Steroid Receptor Action?[J].Front Immunol,2018,9:611.
[7] Ramanujan SA, Cravens EN, Krishfield SM, et al. Estrog en-Induced hsa-miR-10b-5p Is Elevated in T Cells From Patie nts With Systemic Lupus Erythematosus and Down-Regulates Serine/Arginine-Rich Splicing Factor 1[J].Arthritis Rheuma tol,2021,73(11):2052-8.
[8] Nusbaum JS,Mirza I, Shum J, et al. Sex Differences in Systemic Lupus Erythematosus: Epidemiology, Clinical Conside
[9] Kim JW,Kim HA,Suh CH,et al.Sex hormones affect the pathogenesis and clinical characteristics of systemic lupus erythematosus[J].Front Med(Lausanne),2022,9:906475.
[10] Rasmussen NS,Draborg AH,Nielsen CT,et al.Antibodies to early EBV, CMV,and HHV6 antigens in systemic lupus erythe matosus patients[J].Scand J Rheumatol,2015,44(2):143-9.
[11] Talotta R,Atzeni F,Laska MJ.Retroviruses in the pathogenesis of systemic lupus erythematosus:Are they potential therapeutic targets?[J].Autoimmunity,2020,53(4):177 -91.
[12] Wu Z,Mei X,Zhao D,et al.DNA methylation modulates HERV-E expression in CD4+ T cells from systemic lupus eryth ematosus patients[J].J Dermatol Sci,2015,77(2):110-6.
[13] Kamen DL.Environmental influences on systemic lupus erythematosus expression[J].Rheum Dis Clin North Am,2014,40 (3):401-12,vii.
[14] Iwata S,Tanaka Y.Association of Viral Infection With the Development and Pathogenesis of Systemic Lupus Erythe matosus[J].Front Med(Lausanne),2022,9:849120.
[15] Li ZX,Zeng S,Wu HX,et al.The risk of systemic lupus erythematosus associated with Epstein-Barr virus infection: a systematic review and meta-analysis[J].Clin Exp Med,2019, 19(1):23-36.
[16] Ball RJ,Avenell A,Aucott L,et al.Systematic review and meta-analysis of the sero-epidemiological association between Epstein-Barr virus and rheumatoid arthritis[J].Arthr itis Res Ther,2015,17:274.
[17] Barbhaiya M,Hart JE, Malspeis S, et al.Association of Ultraviolet-B Radiation and Risk of SLE among Women in the Nurses'Health Studies[J].Arthritis Care Res(Hoboken),2022.
[18] Costenbader KH, Kim DJ, Peerzada J, et al. Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis[J].Arthritis Rheum,2004,50(3):849-57.
[19] Rubin RL,Hermanson TM, Bedrick EJ, et al. Effect of cigarette smoke on autoimmunity in murine and human syste mic lupus erythematosus[J].Toxicol Sci,2005,87(1):86-96.
[20] Wei Q,He J,Wu C,et al.Identification of a circRNA-miRNA -mRNA network to explore the effects of circRNAs on pathoge nesis and treatment of systemic lupus erythematosus[J].Clin Exp Rheumatol,2022.
[21] Singh RP, Hahn BH, Bischoff DS.Identification and Contribution of Inflammation-Induced Novel MicroRNA in the Pathogenesis of Systemic Lupus Erythematosus[J].Front Immu nol,2022,13:848149.
[22] Chen X,Cheng Q, Wu H, et al. Long non-coding RNAs in systemic lupus erythematosus:New insights into disease path ogenesis and diagnosis[J].Scand J Immunol,2022,95(6):e13167.
[23] Liu Q,Deng Y,Li C, et al.LncRNA GAS5 suppressesCD4(+)T cell activation by upregulating E4BP4 via inhibiting miR- 92a-3p in systemic lupus erythematosus[J].Immunol Lett,2020,227:41-7.
[24] Psarras A,Wittmann M,Vital EM. Emerging concepts of type I interferons in SLE pathogenesis and therapy[J].Nat Rev Rheumatol,2022,18(10):575-90.
[25] Loncharich MF, Anderson CW. Interferon Inhibition for Lupus with Anifrolumab:Critical Appraisal of the Evidence Leading to FDA Approval[J].ACR Open Rheumatol,2022,4(6):486 -91.
[26] Scherlinger M,Guillotin V,Douchet I,et al.Selectins impair regulatory T cell function and contribute to systemic lupus erythematosus pathogenesis[J].Sci Transl Med,2021,13(600).
[27] Li H,Boulougoura A, Endo Y, et al. Abnormalities of T cells in systemic lupus erythematosus: new insights in pathog enesis and therapeutic strategies[J].J Autoimmun,2022:102870.
[28] Ghafouri-Fard S,Shahir M,Taheri M, et al.A review on the role of chemokines in the pathogenesis of systemic lupuserythematosus[J].Cytokine,2021,146:155640.